Navigation Links
Tengion Announces European Orphan Drug Designation for Neo-Bladder Augment
Date:4/1/2008

ation, to determine the most effective and efficient regulatory path forward for our neo-organs and neo-tissues."

About Tengion

Tengion, a clinical stage biotechnology company, focuses on developing, manufacturing and commercializing human neo-organs and neo-tissues using our Autologous Organ Regeneration Platform(TM). Tengion uses biocompatible materials and a patient's own (autologous) cells to create a functional neo- organ or neo-tissue that is designed to harness an individual's ability to regenerate specific organ tissue, catalyzing the body's innate ability to regenerate. Tengion's product candidates may ultimately address the most critical problems facing organ and tissue failure patients, enabling people to lead healthier lives without donor transplants or the side effects of related therapies. For more information on the company and current clinical trials, visit Tengion online at: http://www.tengion.com.


'/>"/>
SOURCE Tengion Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Tengion Appoints Jeff Randall to Board of Directors
2. Tengion to Present at Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
3. Preclinical Efficacy Data Demonstrate Ability of Tengions Neo-Bladder Augment to Restore Bladder Function
4. DiObex Announces Presentation of Scientific Poster at Annual Meeting of American Society for Clinical Pharmacology and Therapeutics
5. DaVita Announces Retirement of Former Chief Medical Officer Charles J. McAllister, M.D.
6. Human Pheromone Sciences Announces Quarterly and Full Year Results
7. Dragon Pharma announces 2007 full year financial results
8. Genaera Corporation Announces 2007 Financial Results
9. Genmab Announces Year End 2007 Financial Results
10. Immunosyn Corporation Announces 2007 Results, Files 10KSB
11. Elbit Imaging Ltd. Announces Results For Fiscal Year 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... 23, 2014 According to Ross Selinger, President ... of ITRA Global, the national office market continues to be ... This is evidenced by the third quarter’s surprising 3.9% GDP, ... Low energy costs have held inflation down and the Fed ... the housing market remaining soft. , This solid economic news ...
(Date:12/24/2014)... 2014 Pipette.com announces their Holiday ... can submit their #HolidayInTheLab pictures for a chance to ... , For those struggling to think of a holiday ... in the Lab Contest provides the ideal holiday presents. ... to send pictures of their chemistree, holiday sweaters, as ...
(Date:12/24/2014)... LOUIS , Dec. 23, 2014 ... today that the waiting period under the Hart-Scott-Rodino ... the acquisition expired on December 22, 2014, thereby ... review requirement for the acquisition of the Company ... U.S. antitrust clearance satisfies another condition to closing ...
(Date:12/22/2014)... , Dec. 22, 2014   Synthetic ... developer of pathogen-specific therapies for serious infections ... the microbiome, today announced positive topline safety ... clinical trial of SYN-004, the Company,s investigational ... Clostridium difficile (C. difficile) infection, ...
Breaking Biology Technology:ITRA Global Reports Long Island Is Out of Sync With The National Office Market 2ITRA Global Reports Long Island Is Out of Sync With The National Office Market 3Major Pipette Distributor Pipette.com Announces their Holiday in the Lab Contest 2Acquisition of Sigma-Aldrich by Merck KGaA, Darmstadt, Germany, Receives U.S. Antitrust Clearance 2Acquisition of Sigma-Aldrich by Merck KGaA, Darmstadt, Germany, Receives U.S. Antitrust Clearance 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 2Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 4Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 5
... Calif. , July 29 Isis Pharmaceuticals, Inc. (Nasdaq: ISIS ... payment from GlaxoSmithKline (NYSE: GSK ) related to the designation as ... disease.  Isis will develop the drug to Phase 2 proof-of-concept, at which time ... , , ...
... LONDON , July 29, ... the appointment of Dr Neill Moray Mackenzie to the ... a long record of executive,board level management within the ... Oxford Biomedica plc (an LSE,listed company), Avidex Ltd (now ...
... July 28 /PRNewswire-FirstCall/ - Angiotech Pharmaceuticals, ... Athersys, Inc. (NASDAQ: ATHX) announced positive results from ... allogeneic cell therapy product, administered to individuals following ... as a heart attack. The study results, which ...
Cached Biology Technology:Isis Earns $5 Million Milestone Payment From GSK for Designation of a Development Candidate to Treat an Undisclosed Rare and Serious Disease 2Isis Earns $5 Million Milestone Payment From GSK for Designation of a Development Candidate to Treat an Undisclosed Rare and Serious Disease 3CMP Therapeutics Appoints Dr Neill Moray Mackenzie as CEO 2CMP Therapeutics Appoints Dr Neill Moray Mackenzie as CEO 3CMP Therapeutics Appoints Dr Neill Moray Mackenzie as CEO 4CMP Therapeutics Appoints Dr Neill Moray Mackenzie as CEO 5Angiotech Pharmaceuticals and partner Athersys announce positive results from phase I study of MultiStem(R) in heart attack patients 2Angiotech Pharmaceuticals and partner Athersys announce positive results from phase I study of MultiStem(R) in heart attack patients 3Angiotech Pharmaceuticals and partner Athersys announce positive results from phase I study of MultiStem(R) in heart attack patients 4Angiotech Pharmaceuticals and partner Athersys announce positive results from phase I study of MultiStem(R) in heart attack patients 5Angiotech Pharmaceuticals and partner Athersys announce positive results from phase I study of MultiStem(R) in heart attack patients 6Angiotech Pharmaceuticals and partner Athersys announce positive results from phase I study of MultiStem(R) in heart attack patients 7Angiotech Pharmaceuticals and partner Athersys announce positive results from phase I study of MultiStem(R) in heart attack patients 8Angiotech Pharmaceuticals and partner Athersys announce positive results from phase I study of MultiStem(R) in heart attack patients 9
(Date:12/19/2014)...  23andMe, Inc., the leading personal genetics company, today ... differences in genetic ancestry of individuals from across ... immigrants first arrived more than four hundred years ago, ... as a meeting place for peoples from different continents. ... mixing of peoples with African, European, and American origins ...
(Date:12/17/2014)... Dec. 15, 2014  HITLAB SM announced ... (GCP) audit to confirm its adherence to current ... accomplishment enables HITLAB to conduct regulated smart device ... principles for patient safety and research quality. ... access, quality, and delivery with innovative technology," said ...
(Date:12/15/2014)... Dec. 12, 2014 Research and Markets ... of the "Global Facial Recognition Market 2015-2019" ... http://photos.prnewswire.com/prnh/20130307/600769 Facial recognition ... individuals. Facial recognition system measures the overall facial ... edges, mouth, and the distance between eyes. Facial ...
Breaking Biology News(10 mins):23andMe Study Sketches Genetic Portrait of the United States 223andMe Study Sketches Genetic Portrait of the United States 323andMe Study Sketches Genetic Portrait of the United States 4HITLAB Completes GCP Audit for FDA Smart Device & App Compliance 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 3
... the experience of having pet animals in their houses have ... seem to recognize our faces, our voices and our smell. ... other people. , Actually, this is not just a gut ... honey bees, chickens, pigeons, sheep, dogs, llamas, penguins, seals, rabbits, ...
... The University of California, Riverside has signed an exclusive ... South African company, to market ,GEM, an avocado variety ... the agreement signed last month, Westfalia will be UC ... Currently, in the United States, the Californiabased Brokaw Nursery ...
... Biologists at UC San Diego have discovered that an important ... or iPSCs, derived from an individual,s own cells, could face ... cell therapies. In today,s advance online issue of the ... evidence of immune system rejection of cells derived from autologous ...
Cached Biology News:I know you, bad guy! 2I know you, bad guy! 3UC Riverside licenses leading South African company to market 'GEM' avocados 2UC Riverside licenses leading South African company to market 'GEM' avocados 3Study finds therapies using induced pluripotent stem cells could encounter immune rejection problems 2
...
Experion spin filters are used to filter the gel matrix and gel stain solution prior to use with the Experion automated electrophoresis system. Supplied as 10 spin filters....
... use in the Microsart e.motion are sterile-sealed, without ... a specially designed individual package on a band. ... of membrane filter units ensures that they are ... sealed band guarantees uniform dispensing of the individual ...
... The model 55S Rocking Shaker provides ... and blotted membranes. The very slow ... degree of tilt provide a gentle ... over gels and blotted membranes to ...
Biology Products: